Growth funding Velentium Medical recently secured $15 million in growth financing from Trinity Capital, signaling strong investor confidence and potential for accelerated expansion in design and manufacturing capabilities. This creates an opportunity to engage for expanded CDMO services, capacity, and advanced manufacturing programs.

Active implant focus Specialization in active implants, neuromodulation, deep brain stimulation, cardiac management, and diabetes management positions Velentium as a strategic partner for high-complexity devices requiring end-to-end development, regulatory readiness, cybersecurity, and robust test systems.

Cybersecurity training With established cybersecurity offerings and training programs, there is a sales path to provide ongoing security-embedded development services, secure product lifecycle support, and bespoke cybersecurity credentialing for clients pursuing stringent regulatory approvals.

Full-service CDMO As a full-service in-house CDMO spanning design to manufacture for Class II to Class III devices, Velentium can be positioned to take on startups and Fortune 100 clients alike, offering scalable engagement models, risk-sharing collaborations, and turnkey program management.

Tech and collaboration Utilizing a modern tech stack and established partnerships (Jira, Jama Software, Google Cloud, university collaborations) creates a compelling case for selling integrated program collaboration, process transparency, and accelerated time-to-market through structured, collaborative development platforms.